MidregiOnal proatrial natriuretic peptide to guide SEcondary Stroke prevention: The MOSES-study. An international, multicentre, randomised-controlled, two-arm, assessor-blinded trial.

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517600-11-01

Acronym

MOSES

Enrollment

190

Registered

2025-01-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Brief summary

The primary outcome measure is the time to any recurrent stroke within 1 year after the index ischemic stroke.

Detailed description

Composite of major bleeding, recurrent stroke and/or vascular death (whichever occurs first) within 1 year after the index ischemic stroke; single components of the composite outcome above

Interventions

DRUGPradaxa 110 mg hard capsules

DRUGPradaxa 150 mg hard capsules

DRUGEliquis 2.5 mg film-coated tablets

DRUGLixiana 30 mg film-coated tablets

DRUGLixiana 60 mg film-coated tablets

DRUGEliquis 5 mg film-coated tablets

DRUGAspirine 100

DRUG100 mg Tabletten

DRUGPlavix 75 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary outcome measure is the time to any recurrent stroke within 1 year after the index ischemic stroke.	—

Secondary

Measure	Time frame
Composite of major bleeding, recurrent stroke and/or vascular death (whichever occurs first) within 1 year after the index ischemic stroke; single components of the composite outcome above	—

Countries

Greece, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026